Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.

Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S.

Acta Neuropathol Commun. 2013 Dec 23;1:84. doi: 10.1186/2051-5960-1-84.

2.

Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.

Jackson SJ, Lee J, Nikodemova M, Fabry Z, Duncan ID.

J Neuropathol Exp Neurol. 2009 Jun;68(6):616-25. doi: 10.1097/NEN.0b013e3181a41d23.

3.

Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.

Papadopoulos D, Pham-Dinh D, Reynolds R.

Exp Neurol. 2006 Feb;197(2):373-85. Epub 2005 Dec 9.

PMID:
16337942
4.

An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss.

Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJ, Baker D, Chandran S.

J Neuroimmunol. 2008 Sep 15;201-202:200-11. doi: 10.1016/j.jneuroim.2008.05.034. Epub 2008 Jul 30.

PMID:
18672298
5.

Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.

Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V, Arnon R.

J Autoimmun. 2011 Nov;37(3):228-41. doi: 10.1016/j.jaut.2011.06.003. Epub 2011 Jul 14.

PMID:
21752599
6.

Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response.

Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J, Quandt JA, Bratincsak A, Shahar T, Eusebi F, Sherman LS, Mattson MP, Martin R, Rao MS.

J Neuropathol Exp Neurol. 2007 Jul;66(7):637-49.

7.

Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.

Berard JL, Wolak K, Fournier S, David S.

Glia. 2010 Mar;58(4):434-45. doi: 10.1002/glia.20935.

PMID:
19780195
8.
9.

Impact of pregabalin treatment on synaptic plasticity and glial reactivity during the course of experimental autoimmune encephalomyelitis.

Silva GA, Pradella F, Moraes A, Farias A, dos Santos LM, de Oliveira AL.

Brain Behav. 2014;4(6):925-35. doi: 10.1002/brb3.276. Epub 2014 Sep 2.

10.

Differential aspects of immune cell infiltration and neurodegeneration in acute and relapse experimental autoimmune encephalomyelitis.

Soellner IA, Rabe J, Mauri V, Kaufmann J, Addicks K, Kuerten S.

Clin Immunol. 2013 Dec;149(3):519-29. doi: 10.1016/j.clim.2013.10.011. Epub 2013 Oct 27.

PMID:
24239839
11.

Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice.

Peferoen LA, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EH, van der Valk P, Pryce G, van Noort JM, Baker D, Amor S.

Immunology. 2016 Oct;149(2):146-56. doi: 10.1111/imm.12644. Epub 2016 Aug 9.

PMID:
27388634
12.

Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.

Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D.

Mult Scler. 2011 Aug;17(8):939-48. doi: 10.1177/1352458511400476. Epub 2011 Apr 1.

PMID:
21459808
13.

Neurodegeneration and inflammation in hippocampus in experimental autoimmune encephalomyelitis induced in rats by one--time administration of encephalitogenic T cells.

Kurkowska-Jastrzębska I, Swiątkiewicz M, Zaremba M, Cudna A, Piechal A, Pyrzanowska J, Widy-Tyszkiewicz E, Członkowska A.

Neuroscience. 2013 Sep 17;248:690-8. doi: 10.1016/j.neuroscience.2013.06.025. Epub 2013 Jun 24.

PMID:
23806721
14.
15.

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.

Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N.

Neuroscience. 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.

PMID:
25637488
16.

Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.

Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D.

Mult Scler Relat Disord. 2012 Jan;1(1):29-38. doi: 10.1016/j.msard.2011.09.001. Epub 2011 Sep 15.

PMID:
25876448
17.

Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective.

Skundric DS.

Curr Neurovasc Res. 2005 Oct;2(4):349-62. Review.

PMID:
16181126
18.

Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.

Hammer LA, Zagon IS, McLaughlin PJ.

Brain Res Bull. 2013 Sep;98:122-31. doi: 10.1016/j.brainresbull.2013.08.001. Epub 2013 Aug 22.

PMID:
23973432
19.

Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.

Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, Siatskas C, Litwak S, Fehlings MG, Strittmatter SM, Bernard CC.

Brain. 2012 Jun;135(Pt 6):1794-818. doi: 10.1093/brain/aws100. Epub 2012 Apr 28.

20.

Neurodegeneration in autoimmune CNS inflammation.

Herz J, Zipp F, Siffrin V.

Exp Neurol. 2010 Sep;225(1):9-17. doi: 10.1016/j.expneurol.2009.11.019. Epub 2009 Dec 1. Review.

PMID:
19961850
Items per page

Supplemental Content

Write to the Help Desk